GlassScriptPhysician profile
Charles J Wanker
NPI 1609835446
$544.10
in general payments reported to CMS, 2019-2025
14 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.24 · 2020: $79.29 · 2021: $27.34 · 2022: $43.17 · 2023: $112 · 2024: $111 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.17 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $86.05 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $82.31 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $72.79 | 2020-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $60.56 | 2020-2025 | Farxiga |
| Abbvie INC. | $53.97 | 2023-2025 | Vraylar |
| Amgen INC. | $41.67 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.13 | 2023 | Jardiance |
| Allergan, INC. | $23.25 | 2020 | |
| Medtronic Minimed, INC. | $18.24 | 2019 | |
| Sumitomo Pharma America, INC. | $17.84 | 2024 | Gemtesa |
| Abbott Laboratories | $15.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $14.43 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $13.72 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wanker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.